louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02572869: Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
Official title: Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Head and Neck Cancer
Keywords: Mandible Reconstruction
Fibula Osteomyocutaneous Free Flaps
Quality of Life
15-244
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2015-10-09
Enrollment: 26
Sex: ALL
Minimum age (years): 25
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All eligible patients will be identified from the institutional databases. Preliminary queries indicate that approximately 61 patients are eligible and currently alive.

Brief summary: The purpose of this study is to assess the functional and esthetic outcomes in patients who had removal of a part of the lower jaw bone due to mouth cancer and reconstruction of the jaw bone with a bone ( fibula) from the leg at MSKCC between the years 1987 to 2014.


Eligibility criteria: Inclusion Criteria:

* Able to read and write in the English language
* Patients who underwent segmental mandibulectomy and free fibular flap reconstruction at MSK between 1987 and 2014
* Able to travel to the MSK outpatient clinic or have access to email, the MSK patient portal and a computer with a camera for the follow up examination by a physician and completion of the questionnaires.

Exclusion Criteria:

* Patients who underwent marginal mandibulectomy
* Patients who underwent mandibular reconstruction with a different type of vascularized bone free flap
* Patients who underwent mandibular reconstruction with soft tissue free flap

Primary outcomes:
measure: Long-term functional (11-item clinical examination form which documents the patient's oral function)
timeFrame: 1 year
measure: Long-term aesthetic outcome evaluated by photographs
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Basking Ridge
country: United States
facility: Memoral Sloan Kettering Cancer Center
state: New Jersey
city: Harrison
country: United States
facility: Memorial Sloan Kettering West Harrison
state: New York
city: New York
country: United States
facility: Memorial Sloan-Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Jatin Shah, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04898946: Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong
Official title: Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Covid-19 Vaccine
Lead sponsor: Hong Kong Sanatorium & Hospital
Sponsor class: INDUSTRY
First posted: 2021-05-24
Enrollment: 480
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Healthcare workers of HKSH who plan to receive COVID-19 vaccine

Brief summary: Since the first local case of COVID-19 confirmed on 4 Feb 2020, Hong Kong has already experienced 4 waves of COVID-19 surge, with more than 9000 cases reported. A number of vaccines have been shown to be efficacious against symptomatic and severe infection by inducing neutralizing antibody (NAB) against spike protein of the SARS-CoV-2 virus. However, the duration of protection and longevity of antibody response is unknown.

Health care workers (HCWs) who are planning to receive COVID-19 vaccine will be recruited. The level of antibody against spike protein by different quantitative assays will also be serially measured .


Eligibility criteria: Inclusion Criteria:

1. Any staff, visiting doctor, nursing student of HKSH who are aged 18 or above
2. No contraindication for COVID-19 vaccination and plan to receive the intended dosages at the appropriate interval.
3. A baseline serology taken within 1 week before vaccination shows no evidence of recent infection.
4. No history of documented COVID-19 infection

Exclusion Criteria:

-

Primary outcomes:
measure: Change of IgG Level in the serum of healthcare workers who received COVID-19 vaccine
timeFrame: 1 month, 3 months and 6 months post vaccination
Secondary outcomes:
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: Hong Kong Sanatorium & Hospital
Study officials:
affiliation: Hong Kong Sanatorium & Hotel
name: Jonpaul Sze Tsing Zee, MBChB
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03744546: Expanded Access to ABBV-8E12
Official title: Expanded Access to ABBV-8E12
Study type: EXPANDED_ACCESS
Overall status: NO_LONGER_AVAILABLE
Conditions: Primary Tauopathy Corticobasal Degeneration Syndrome (CBD)
Keywords: Expanded Access, Pre-approval Access, Compassionate Use, Special Access Program, Named Patient Basis, Special Access Scheme.
Lead sponsor: AbbVie
Sponsor class: INDUSTRY
First posted: 2018-11-16
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABBV-8E12 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.



Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: AbbVie
name: AbbVie Inc.
role: STUDY_DIRECTOR
References:
Clinical trial NCT03377946: Effect of Probiotics on Pre-diabetes and Diabetes in China
Official title: Effect of Probiotics on Pre-diabetes and Diabetes in China-the Role of Gut Microbiota Composition
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Type 2 Diabetes Mellitus
Keywords: pre-diabetes,diabetes,probiotics
Lead sponsor: Chinese PLA General Hospital
Sponsor class: OTHER
First posted: 2017-12-19
Enrollment: 220
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is aimed at verifying the effects of probiotics (KAWAI:dead S.thermophilus) on glucos management among T2DM and pre-diabetes Chinese adult. Additionally, the investigators intend to verify the effects of probiotics on modifying the structure and function of gut microbiome.

Detailed description: Methods: double-blind, randomized controlled trial. Number of participants: 160 patients with pre-diabetes and 60 diabetes. Intervention time: 3months. Data and Specimen collection time: at baseline and after the intervention.

Observation index

1. Physical measurement: gender, age, weight, BMI, waist circumference, hip circumference, waist-to-hip ratio, systolic pressure, diastolic blood pressure.
2. Lifestyle questionnaire: diet, drinking, exercise, sleep and other habits.
3. Blood test: blood glucose, OGTT, blood lipid, TNF-a, il-6, il-10, LPS, glp-1, gut microbiome metabolism products, T2DM related methylation.

4. Gut microbiome detection: gut microbiome 16Sr DNA sequencing, gut microbiome bioinformatics analysis

Eligibility criteria: Inclusion Criteria:

1. Meet Diabetes/pre-diabetes diagnostic criteria
2. BMI 18-35kg/m2

Exclusion Criteria:

1. Patients with diabetes or hyperlipidemia, and need regular use of drugs.
2. Secondary obesity or diabetes
3. Digestive, tumor, heart, lung, kidney, rheumatic immunity and other systemic serious diseases
4. Pregnant women, women ready for pregnancy, and nursing mothers
5. Take antibiotics or bacterial agents within 1 month
6. Diarrhea or abscess in 1 month or blood or other abnormal feces
7. Diabetics have a history of more than 2 years
8. The OGTT experiment of diabetic patients FG≥9mmol/L or 2h≥14mmol/L

Primary outcomes:
measure: Changes of blood glucose and insulin sensitivity
timeFrame: 3~5 years
measure: Changes of gut microbiota composition
timeFrame: 3~5 years
Secondary outcomes:
measure: Changes of blood inflammatory markers
timeFrame: 3~5 years
measure: Composite changes in diabetes risk factors
timeFrame: 3~5 years
measure: Composite changes of weight, waist circumference and BMI
timeFrame: 3~5 years
Other outcomes:
measure: Changes of Intestinal endocrine function
timeFrame: 3~5 years
Locations:
city: Chongqing
country: China
facility: health management center,Southwest hospital
state: Chongqing
Study officials:
affiliation: Chinese PLA General Hospital
name: Qiang Zeng, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01433146: Effect of Temperament, Anxiety and Depression on Immuninity in Colorectal Cancer Patients. Effetti Del Temperamento, Dell'Ansia e Della Depressione Sulla Sopravvivenza Globale e Sulla Risposta Immunitaria Del Paziente Affetto da Adenocarcinoma Colo-Rettale.
Official title: Effect of Temperament, Anxiety and Depression on Immuninity in Colorectal Cancer Patients.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Temperament
Anxiety
Depression
Colorectal Cancer
Keywords: Temperament
Anxiety
Depression
Colorectal Cancer
Lead sponsor: University of Roma La Sapienza
Sponsor class: OTHER
First posted: 2011-09-13
Enrollment: 120
Sex: ALL
Minimum age (years): 30
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Primary care clinic

Brief summary: Aim of the study is to evaluate if Temperament, Anxiety and Depression can affect Immunity and influence Survival in Colorectal Cancer Patients

Detailed description: 120 prospective patients, with non-metastatic colorectal cancer, will be evaluated with questionnaires and auto-questionnaires in order to assess temperament, anxiety and depression. The immunity status will be assessed by a blood sample with the aim to evaluate cell-mediated immunity.

Survivall will be related to level of anxiety/temperament/depression and cell-mediated immunity.

Univariate and multivariate model analisys will be performed in order to evaluate if anxiety/temperament/depression and cell-mediated immunity can be considered as prognostic factors.

Eligibility criteria: Inclusion Criteria:

diagnosis of non-metastatic colorectal cancer

Exclusion Criteria:

previous other primary malignancies immunodepression diagnosis of major deppression diagnosis of anxiety/depression syndrome

Primary outcomes:
measure: Temperament in non-metastatic colorectal cancer patients
timeFrame: 24 months
Secondary outcomes:
Other outcomes:
Locations:
city: Rome
country: Italy
facility: "Sapienza" University of Rome
Study officials:
affiliation: University of Roma La Sapienza
name: Marco La Torre, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Nan KJ, Wei YC, Zhou FL, Li CL, Sui CG, Hui LY, Gao CG. Effects of depression on parameters of cell-mediated immunity in patients with digestive tract cancers. World J Gastroenterol. 2004 Jan 15;10(2):268-72. doi: 10.3748/wjg.v10.i2.268.
citation: Kohno Y, Maruyama M, Matsuoka Y, Matsushita T, Koeda M, Matsushima E. Relationship of psychological characteristics and self-efficacy in gastrointestinal cancer survivors. Psychooncology. 2010 Jan;19(1):71-6. doi: 10.1002/pon.1531.
Clinical trial NCT03319446: Collection of Anonymized Samples
Official title: Collection of Anonymized Samples for Use in Product Development and Clinical Trials
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Healthy
Respiratory Disease
Gastrointestinal Disease
Lead sponsor: BioFire Diagnostics, LLC
Sponsor class: INDUSTRY
First posted: 2017-10-24
Enrollment: 1500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Employees of BioFire Diagnostics, and the general community of the greater Salt Lake City area.

Brief summary: This is a generic sample collection study for collecting blood, stool, rectal swabs, nasal washes, nasopharyngeal aspirates, nasopharyngeal swabs, throat swabs, nasal swabs, and urine from human sources. Subjects will be recruited from BioFire Diagnostics employees and from the general community. Subjects may be asked about recent or ongoing illness at the time of specimen collection and these symptoms will be recorded and attached to the sample. No other identifying information will be collected and the samples will be kept anonymous.The samples may be used internally or by external sites, such as the clinical study sites, for evaluating and determining performance characteristics of in vitro diagnostic devices.


Eligibility criteria: Inclusion Criteria:

* Consenting adult

Exclusion Criteria:

* Weigh less that 110 lb for blood collection

Primary outcomes:
measure: PCR Amplification Curves
timeFrame: 10 years
Secondary outcomes:
Other outcomes:
Locations:
city: Salt Lake City
country: United States
facility: BioFire Diagnostics
state: Utah
Study officials:
References:
Clinical trial NCT06835946: Impact of Anesthesia, Positive Pressure Ventilation and Modality of Imaging on the Echocardiographic Assessment of the Severity of Aortic Regurgitation
Official title: Prospective Single-center Observational Trial Aimed at Investigating the Effect of General Anesthesia, Positive Pressure Ventilation and Change of Imaging Modality From Transthoracic Echo to Transesophageal Echo on the Grading of the Severity of Aortic Regurgitation.
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Aortic Regurgitation Disease
Aortic Insufficiency
Lead sponsor: University of Liege
Sponsor class: OTHER
First posted: 2025-02-19
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients scheduled for cardiac surgery at the "Centre Hospitalier Universitaire de Liège" with any grade of known preoperative aortic regurgitation.

Brief summary: The goal of this observational study is to assess the impact of imaging modality (trans-thoracic echo (TTE) vs trans-esophageal echo (TEE)), anesthesia and positive pressure ventilation on the grading of aortic insufficiency.

Patients scheduled for cardiac surgery and in whom a TEE is going to be performed intra-operatively will be enrolled. The grading of the aortic insufficiency will be compared between a TTE performed immediately before the induction of general anesthesia end the TEE performed after induction of general anesthesia.


Eligibility criteria: Inclusion Criteria:

* Known aortic regurgitation of any grade
* Scheduled for a cardiac surgery procedure during which a trans-esophageal echo is planned.

Exclusion Criteria:

* Non sinus rhythm
* Mitral regurgitation more than mild.
* Pre-operative critical state (according to the definition of the EuroSCORE II)
* Presence of a prosthetic aortic valve
* Contra-indication to trans-esophageal echo

Primary outcomes:
measure: Concordance between the grade of aortic regurgitation on pre-operative TTE and intra-operative TEE
timeFrame: From enrollment to the end of the pre-operative trans-esophageal echo
Secondary outcomes:
measure: Concordance between the grade of aortic regurgitation based on the pre-operative trans-thoracic echo and a trans-thoracic echo repeated immediately after induction of anesthesia.
timeFrame: Enrollment to end of pre-operative trans-thoracic echo
Other outcomes:
Locations:
city: Liège
country: Belgium
facility: Centre Hospitalier Universitaire de Liège
Study officials:
References:
Clinical trial NCT06514846: Utilizing the Michigan Neuropathy Screening Instrument for Early Detection of Diabetic Neuropathy
Official title: Utilizing the Michigan Neuropathy Screening Instrument, Routine Nerve Conduction Study (NCS), and Nerve Ultrasound for Early Detection of Diabetic Neuropathy
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Diabetic Polyneuropathy
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2024-07-23
Enrollment: 100
Sex: ALL
Minimum age (years): 33
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Place of study: Participants will be recruited from the diabetes clinic, Sohag university hospital.

* Type of the study: Cross-Sectional Comparative study.
* Patients:

v Study group: participants of the study will meet the following criteria:

Ø Inclusion criteria:

ü Age: 30-55 y

ü Type of diabetes: Type 2

ü Duration of diabetes: Within 1Year of diagnosis of Type 2 diabetes mellitus according to World Health Organization 1999 criteria

ü Gender: Both males \& females

Ø Exclusion criteria:

Patients who had known conditions that could present with neuropathy such as hereditary sensory neuropathy, vitamin B12 or folate deficiency, paraneoplastic conditions, autoimmune diseases, uremia, hypothyroidism, and ethanol abuse.

Brief summary: The study aims to Compare the diagnostic accuracy of the Michigan Neuropathy Screening Instrument (MNSI) (using MNS questionnaire, ,Inspection, vibratory sensation, Ankle reflexes Exam, 10 g monofilament needle examination), routine NCS, and the U/S of the median, posterior tibial, and sural nerves in identifying diabetic peripheral neuropathy in patients recently diagnosed with type 2 diabetes.


Eligibility criteria: Inclusion Criteria:

* ü Age: 30-55 y

ü Type of diabetes: Type 2

ü Duration of diabetes: Within 1Year of diagnosis of Type 2 diabetes mellitus according to World Health Organization 1999 criteria

Exclusion Criteria:

* Patients who had known conditions that could present with neuropathy such as hereditary sensory neuropathy, vitamin B12 or folate deficiency, paraneoplastic conditions, autoimmune diseases, uremia, hypothyroidism, and ethanol abuse.

Primary outcomes:
measure: Early detection of Diabetic Neuropathy
timeFrame: Searching in patients diagnosed within 1 year or less
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Faculty of medecine Sohag university
Study officials:
References:
Clinical trial NCT05236946: Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT
Official title: Observation or Upfront Cranial RT in Oncogene Driver Mutated NSCLC With Asymptomatic Brain Metastases: A Phase III Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Asymptomatic Brain Metastases
Driver Mutation Positive Non-small Cell Lung Cancer
Keywords: Asymptomatic brain metastases
EGFR mutation
Whole brain radiotherapy
Stereotactic radiosurgery
ALK rearrangement
Lead sponsor: Tata Memorial Hospital
Sponsor class: OTHER_GOV
First posted: 2022-02-11
Enrollment: 190
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Tyrosine Kinase Inhibitors (TKIs) especially higher generation TKI have higher CNS penetration rates and have shown favorable response rates in brain metastases. Brain radiotherapy/surgery is the standard treatment in brain metastases especially symptomatic metastases, however, the role of local treatment especially in driver mutation-positive non-small cell lung cancer with asymptomatic brain metastases is being questioned given their potential side effects. No randomized trial has shown the superiority of early vs delayed cranial RT in asymptomatic BM of driver mutated NSCLC.


Eligibility criteria: Inclusion Criteria:

1. Age ≥ 18 years
2. Patients with ECOG performance status of 0-2
3. Patients with pathologically proven diagnosis of NSCLC
4. Patients with positive oncogene mutation status (EGFR/ALK)
5. Patients with radiologically confirmed parenchymal brain metastases
6. Patients with asymptomatic Synchronous or Metachronous brain metastases
7. Patients willing for written informed consent and must be willing to comply with the specified follow-up schedule

Exclusion Criteria:

1. Patients with CSF dissemination only without any parenchymal brain metastases
2. Patients with brain metastases in the brain stem
3. Patients with prior history of radiation therapy to the brain
4. Patient not suitable for TKI therapy as per the medical oncologist
5. Pregnant or lactating females

Primary outcomes:
measure: Intracranial progression free survival at 24 months
timeFrame: 2 year
Secondary outcomes:
measure: Overall Survival
timeFrame: Upto 5-year
measure: Progression free survival
timeFrame: upto 2 year
measure: Neurocognition toxicity
timeFrame: Upto 12 months
measure: Toxicity using CTC v5.1
timeFrame: Upto 2 years
measure: Local Control
timeFrame: Upto 2 years
Other outcomes:
Locations:
city: Mumbai
country: India
facility: Tata Memorial Hospital
state: Maharashtra
Study officials:
References:
Clinical trial NCT07020546: Ovarian PRP Injections for Improved Embryo Quality Using Embryo Quality Score
Official title: Ovarian Platelet-Rich Plasma (oPRP) Injections Improvement In IVF Patients Based On Time-Lapse Incubator Culture for Automated Tracking and AI for Embryo Quality Assessment : A Non-Randomized Propsective Self-Controlled Interventional Study
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Infertility
Poor Ovarian Reserve
Embryo Growth Disorder
in Vitro Fertilization
Lead sponsor: Generation Next Fertility
Sponsor class: OTHER
First posted: 2025-06-13
Enrollment: 180
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 47
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: A NON-RANDOMIZED PROSPECTIVE SELF-CONTROLLED INTERVENTIONAL STUDY
Primary purpose: TREATMENT

Brief summary: Patients will have ovarian PRP treatments and embryo development will be observed using time-lapse imaging and AI software.

Detailed description: . oPRP Treatment \& Second IVF Cycle (Study Cycle)

* Following the first IVF cycle, patients will undergo their first oPRP injection:

  * Timing: 1-2 weeks after the onset of the next menstrual cycle.
  * Procedure: Under IV sedation, a patient's autologous PRP will be prepared and injected directly into both ovaries under transvaginal ultrasound guidance.
* Second IVF Cycle (oPRP Study Cycle)

  * The same ovarian stimulation protocol will be used for consistency.
  * A second oPRP injection will be performed on stimulation days 2-5 to enhance folliculogenesis.
  * Ovulation will be triggered at the same follicular size thresholds, and oocyte retrieval will follow identical protocols.
  * Fertilization methodology will be identical to the first cycle unless no fertilization is identified in the first cycle.
  * Embryo Development Analysis: Up to 15 embryos will be cultured in the AI incubator, where time-lapse imaging will track their morphokinetics, and AI-based analysis will assess embryo viability and implantation potential.

Eligibility criteria: Inclusion Criteria:

* No none contraindications to IVF or PRP treatment
* Adequate ovarian reserves and AMH level
* Willingness to undergo two IVF cycles and oPRP treatment

Exclusion Criteria:

* Anovulation due to menopause or perimenopause
* Any health conditions that are contraindicated for IVF or oPRP treatment

Primary outcomes:
measure: Blastocyst formation and embryo quality
timeFrame: 1 year
Secondary outcomes:
measure: Live birth rate per transfer
timeFrame: 2 years
Other outcomes:
Locations:
Study officials:
affiliation: Generation Next Fertility
name: Jesse Hade, MD
role: PRINCIPAL_INVESTIGATOR
References: